X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA IPCA LABS NATCO PHARMA/
IPCA LABS
 
P/E (TTM) x 30.9 39.8 77.6% View Chart
P/BV x 23.4 3.1 766.3% View Chart
Dividend Yield % 0.5 0.2 290.6%  

Financials

 NATCO PHARMA   IPCA LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
IPCA LABS
Mar-17
NATCO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs877643 136.4%   
Low Rs424503 84.2%   
Sales per share (Unadj.) Rs223.4254.4 87.8%  
Earnings per share (Unadj.) Rs31.116.1 193.3%  
Cash flow per share (Unadj.) Rs40.329.8 135.3%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.80.2 440.5%  
Book value per share (Unadj.) Rs219.5194.6 112.8%  
Shares outstanding (eoy) m33.07126.20 26.2%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.3 129.2%   
Avg P/E ratio x20.935.7 58.7%  
P/CF ratio (eoy) x16.119.2 83.9%  
Price / Book Value ratio x3.02.9 100.6%  
Dividend payout %16.16.2 258.6%   
Avg Mkt Cap Rs m21,50472,300 29.7%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,1286,960 16.2%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m7,38932,106 23.0%  
Other income Rs m167226 74.0%   
Total revenues Rs m7,55632,332 23.4%   
Gross profit Rs m1,7934,448 40.3%  
Depreciation Rs m3041,730 17.6%   
Interest Rs m366241 152.1%   
Profit before tax Rs m1,2902,703 47.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309675 45.7%   
Profit after tax Rs m1,0272,028 50.7%  
Gross profit margin %24.313.9 175.2%  
Effective tax rate %23.925.0 95.8%   
Net profit margin %13.96.3 220.1%  
BALANCE SHEET DATA
Current assets Rs m3,68117,340 21.2%   
Current liabilities Rs m3,1239,559 32.7%   
Net working cap to sales %7.624.2 31.2%  
Current ratio x1.21.8 65.0%  
Inventory Days Days89100 89.2%  
Debtors Days Days5957 103.2%  
Net fixed assets Rs m7,68520,779 37.0%   
Share capital Rs m331252 131.0%   
"Free" reserves Rs m6,67024,499 27.2%   
Net worth Rs m7,25924,553 29.6%   
Long term debt Rs m9553,517 27.1%   
Total assets Rs m11,95739,595 30.2%  
Interest coverage x4.512.2 37.0%   
Debt to equity ratio x0.10.1 91.8%  
Sales to assets ratio x0.60.8 76.2%   
Return on assets %11.75.7 203.4%  
Return on equity %14.28.3 171.4%  
Return on capital %20.710.5 197.6%  
Exports to sales %39.448.6 80.9%   
Imports to sales %5.714.2 40.0%   
Exports (fob) Rs m2,90815,617 18.6%   
Imports (cif) Rs m4214,571 9.2%   
Fx inflow Rs m3,44515,617 22.1%   
Fx outflow Rs m7035,828 12.1%   
Net fx Rs m2,7439,790 28.0%   
CASH FLOW
From Operations Rs m1,4402,764 52.1%  
From Investments Rs m-1,089-1,432 76.1%  
From Financial Activity Rs m-353-1,591 22.2%  
Net Cashflow Rs m-1-259 0.6%  

Share Holding

Indian Promoters % 52.0 45.9 113.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.4 68.8%  
FIIs % 16.6 25.3 65.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.4 149.4%  
Shareholders   25,395 36,892 68.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  WYETH LTD  ABBOTT INDIA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 23, 2018 03:34 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS